In this free webinar, learn about the benefits of moving beyond traditional site selection models by incorporating patient-centric intelligence into early landscapeIn this free webinar, learn about the benefits of moving beyond traditional site selection models by incorporating patient-centric intelligence into early landscape

Site Selection Solutions Using Patient Insights for Rare Disease Trials, Upcoming Webinar Hosted by Xtalks

2026/01/28 21:47
3 min read

In this free webinar, learn about the benefits of moving beyond traditional site selection models by incorporating patient-centric intelligence into early landscape analysis. Attendees will gain insight into applying a three-pillar, bottom-up approach that combines data intelligence, peer-level investigator outreach and patient organization engagement. The featured speakers will discuss how to identify the right sites and investigators earlier by understanding real-world treatment patterns and the patient journey. Attendees will learn how to improve enrollment feasibility and timelines while supporting more ethical and sustainable rare disease trial designs. The speakers will share real-world case studies demonstrating how patient-informed landscape analysis leads to better trial outcomes.

TORONTO, Jan. 28, 2026 /PRNewswire/ — In rare disease clinical trials, a comprehensive landscape analysis is essential for identifying the right sites, investigators and patient populations to ensure successful enrollment and retention. Traditional approaches rely heavily on published literature and academic networks as well as historical data from past clinical trials, often overlooking critical insights from local treatment patterns and patient communities. This gap can lead to missed opportunities, inaccurate estimation of enrollment potential and prolonged study timelines. This webinar demonstrates how patient-informed landscape analysis can strengthen site-selection decisions, and registration is now open.

To optimize site selection and recruitment for rare disease studies, it is crucial to conduct a systematic assessment of the existing research, development and market environment within the specific indication of interest. Implementing a three-pillar assessment approach that integrates data intelligence, medic-to-medic outreach and patient advocacy engagement supports more informed site-selection decisions earlier in the planning process.

In this webinar, the featured speakers will share practical insights from a landscape analysis approach and demonstrate why early investment in patient-centric intelligence leads to more feasible, ethical and successful rare disease trials.

Topics will include:

  • Leveraging comprehensive data sources to understand the competitive landscape, epidemiology, centers of excellence and historical recruitment performance
  • Conducting structured peer-level conversations with key opinion leaders and investigators to assess scientific interest, patient availability, recruitment potential and protocol feasibility
  • Building relationships with patient organizations to understand the patient journey and uncover site opportunities
  • Sharing of real-world case studies to showcase the value of strategic landscape analysis

Register for this webinar to learn how site selection improves when landscape analysis incorporates patient communities, real-world treatment patterns and site readiness signals.

Join experts from Ergomed Clinical Research, Paula Orandash, Director, Patient Engagement; and Benjamen Varsano, Director, Operational Strategy/Office Director, for the live webinar on Friday, February 20, 2026, at 10am EST (4pm CET/EU-Central).

For more information, or to register for this event, visit Site Selection Solutions Using Patient Insights for Rare Disease Trials.

ABOUT XTALKS

Xtalks — The Life Science Community™ empowers professionals across pharma, biotech, medtech, healthcare and research with the trusted knowledge and collaborative insights that move the industry forward. Powered by Honeycomb Worldwide Inc., Xtalks delivers news, feature articles, webinars, podcasts, videos, expert interviews, curated job opportunities and more designed to support informed decision-making in a fast-evolving sector.

Every year, thousands of professionals rely on Xtalks for timely intelligence, peer perspectives and industry thought leadership. Join our life science community to stay informed, connected and ready for what’s next.

To learn more about Xtalks, visit www.xtalks.com

For information about working with Xtalks to host your webinar, visit https://xtalks.com/partner-with-us/

Contact:
Vera Kovacevic
Tel: +1 (416) 977-6555 x371
Email: vkovacevic@xtalks.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/site-selection-solutions-using-patient-insights-for-rare-disease-trials-upcoming-webinar-hosted-by-xtalks-302672076.html

SOURCE Xtalks

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.
Tags:

You May Also Like

Relax, Core v30 Won’t Kill Bitcoin

Relax, Core v30 Won’t Kill Bitcoin

The post Relax, Core v30 Won’t Kill Bitcoin appeared on BitcoinEthereumNews.com. Key Takeaways The rhetoric on Crypto Twitter has been heating up between Core and Knots in the OP_RETURN saga, as Bitcoin news takes on a new route. Despite some back and forth, Blockstream CEO Adam Back declared he would run Bitcoin Core v30 Despite believing the upgrade will open the network to more spam, Bitcoin OG Jimmy Song reminds people panicking that Core v30 won’t kill Bitcoin In case you missed it, the Bitcoin community is in full battle mode over Bitcoin Core v30 and the so-called OP_RETURN drama. Just mention “Core v30” in a crowded Discord and watch the fireworks. On one side, you’ve got the Bitcoin Knots faithful grabbing pitchforks and talking about the soul of the network; on the other, the Core devs, who take a more laissez-faire approach. Bitcoin News: What’s Actually Happening in Core vs Knots At the heart of the storm? Bitcoin Core’s decision to vastly expand the OP_RETURN data limit in Bitcoin Core v30. For years, Bitcoin’s OP_RETURN opcode, a line of script that lets users immutably store tiny amounts of data on the blockchain, was capped at 80 bytes. With Core v30, that ceiling is yanked off, allowing payloads up to the full block size (nearly 4MB). Proponents see big wins here: more flexibility for on-chain applications, support for digital notarization, and enhanced Layer 2 infrastructure. Critics, especially in the Knots camp, warn that this opens the door to chain bloat, endless spam, and a deviation from Bitcoin’s monetary roots. Knots developers, most notably Luke Dashjr and Samson Mow, argue that without limits, Bitcoin risks becoming a dumping ground for arbitrary data. A fate that would make running a node costly and possibly restrict network participation to large players. Since the Core update was finalized, Knots’ market share of full nodes has…
Share
BitcoinEthereumNews2025/09/24 14:15
United States Building Permits Change dipped from previous -2.8% to -3.7% in August

United States Building Permits Change dipped from previous -2.8% to -3.7% in August

The post United States Building Permits Change dipped from previous -2.8% to -3.7% in August appeared on BitcoinEthereumNews.com. Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page. If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet. FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted. The author and FXStreet are not registered investment advisors and nothing in this article is intended…
Share
BitcoinEthereumNews2025/09/18 02:20
Pi Network Tech Upgrade Unlocks Mainnet Migration for 2.5 Million Users and Introduces Palm Print Security

Pi Network Tech Upgrade Unlocks Mainnet Migration for 2.5 Million Users and Introduces Palm Print Security

Pi Network has announced a major technological breakthrough that marks a new chapter in its evolution. According to information shared by Twitter user @strong3
Share
Hokanews2026/02/07 12:28